nach oben

Erschienen in:

01.05.2003 | Original Article

Polymorphism of the β₃-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine

verfasst von: J.F. Muñoz-Valle, M. Vázquez-Del Mercado, S. Ruiz-Quezada, E. Oregón-Romero, R.E. Navarro-Hernández, J. Ramírez-Barragán, G. Martínez-Bonilla, G. Bernard-Medina, B.E. Bastidas-Ramírez, B. Ruiz-Madrigal, A. Panduro

Erschienen in: Rheumatology International | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

We investigated the effect of beta 3-adrenergic receptor (β₃AR) polymorphism on lipid profiles in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) treated with chloroquine. One hundred sixty-eight subjects were classified into three groups: 61 RA patients, 57 SLE patients, and 50 healthy subjects. All patients fulfilled the 1987 and 1982 classification criteria for RA and SLE, respectively, of the American College of Rheumatology. Demographic data and clinical characteristics of the patients were registered. Fasting lipid profile determination and leukocyte genomic DNA isolation from peripheral blood was performed in all the participants. Screening of the β₃-AR gene polymorphic region (exon 1) was done by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. Quantitative and qualitative variables were analyzed using analysis of variance (ANOVA) with the LSD and χ ² tests, respectively. An association between the arg64/arg64 β₃-AR genotype and high levels of triglycerides (TG) and very low-density lipoprotein cholesterol (VLDL-c) was found in three RA patients (P=0.01), two of them taking chloroquine. Arg64/arg64 β₃-AR polymorphism may contribute to increased TG and VLDL-c in RA patients, independently of chloroquine treatment.

De Blasi A (1990) Beta-adrenergic receptors: structure, function and regulation. Drugs Exp Clin Res 16:107–112PubMed

Emorine LJ, Marullo S, Brien-Sutrend MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD (1989) Molecular characterization of human β3-adrenergic receptor. Science 245:1118–1121PubMed

Strader CD, Sigal IS, Dixon RAF (1989) Structural basis of β-adrenergic receptor function. FASEB J 3:1825–1832PubMed

Strosberg AD (1997) Structure and function of the β₃-adrenergic receptor. Ann Rev Pharmacol Toxicol 37:421–450CrossRef

García-Rubi E, Calles EJ (1999) Insulin resistance and type 2 diabetes mellitus: its relationship with the β3-adrenergic receptor. Arch Med Res 30:459–464CrossRefPubMed

Krief S, Lönnqvist F, Raimbault S, Baude B, Van Sprousen P, Arner P, Strosberg AD, Ricquier D, Emorine L (1993) Tissue distribution of β₃-adrenergic receptor mRNA in man. J Clin Invest 91:344–349PubMed

Lönnqvist F, Thörne A, Nilsell K, Hoffstedt J, Arner P (1995) A pathogenetic role of visceral fat β₃-adrenergic receptors in obesity. J Clin Invest 95:1109–1116PubMed

Walston J, Silver KD, Bogardus C, Knowler WC, Celi FS, Austin S, Manning B, Strosberg AD, Stern MP, Raben N, Sorkin JD, Roth J, Shuldiner AR (1995) Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β₃-adrenergic receptor gene. N Engl J Med 333:343–347PubMed

Clement K, Vaisse C, Manning B, Basdevant A, Guy-Grand B, Ruiz-J, Silver KD, Shuldiner AR, Froguel P, Strosberg AD (1995) Genetic variation in the β₃-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352–354PubMed

10.

Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M (1995) Mutation of β₃-adrenergic receptor gene and response to treatment of obesity. Lancet 346:1433–1434

11.

Sakane N, Yoshida T, Umekawa T, Kondo M, Sakai Y, Takahashi T (1997) β₃-adrenergic receptor polymorphism: a genetic marker for visceral fat obesity and the insulin resistance syndrome. Diabetologia 40:200–204CrossRefPubMed

12.

Kurabayashi T, Carey DGP, Morrison NA (1996) The β₃-adrenergic receptor gene Trp64Arg mutation is overrepresented in obese women. Diabetes 45:1358–1363PubMed

13.

Xiang K, Jia W, Lu H, Zheng T, Lu J, Tang J, Ding W, Sun D, Li J (1998) Effects of Trp64Arg mutation in the β3-adrenergic receptor gene on body fat, plasma glucose level, lipid profile, insulin secretion and action in Chinese. Chung Hua I Chuan Hsueh Tsa Chih 15:337–340

14.

Naoki S, Toshihide Y, Keiji Y, Yoshio N, Tunekazu U, Akinori K, Yasuto T, Motoharu K (1997) β₃-adrenoreceptor gene polymorphism: a newly identified risk factor for proliferative retinopathy in NIDDM patients. Diabetes 46:1633–1636PubMed

15.

Isomaki HA, Mutru O, Koota K (1975) Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 4:205–208PubMed

16.

Mutru O, Laakso M, Isomaki H, Koota K (1985) Ten year mortality and cause of death in patients with RA. BMJ 290:1797–1799PubMed

17.

Pincus T, Callahan LF (1986) Taking mortality in RA seriously—predictive markers, socioeconomic status and co-morbidity. J Rheumatol 13:841–845PubMed

18.

Pinals RS (1987) Survival in rheumatoid arthritis. Arthritis Rheum 30:473–475PubMed

19.

Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, Song CH, Lee J (1999) Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 26:1701–1704PubMed

20.

Ettinger WH, Goldberg AP, Applebaum-Bowden D (1987) Dyslipoproteinemia in systemic lupus erythematosus. Am J Med 83:503–508

21.

Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863PubMed

22.

Rahman P, Urowitz MB, Gladman DD, Bruce IN, Genest JR (1999) Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 26:2363–2368PubMed

23.

Bruce IN, Urowitz MB, Gladman DD, Hallett DC (1999) Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 26:2137–2143PubMed

24.

Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern P (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89:322–326PubMed

25.

Hodis HN, Quismorio FP, Wickham JR, Blankenhorn DH (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 20:661–665PubMed

26.

Wallace DJ (1994) Antimalarial agents and lupus. In: Systemic lupus erythematosus. Rheum Dis Clin North Am 20:243–263PubMed

27.

Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J (1997) Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 3:3–8

28.

Gladman DD, Urowitz MB, Senecal JL, Fortin PJR, Petty RE, Esdaile JM, Carrette S, Edworthy SM, Smith CD, Thorne JC (1998) Workshop report. Aspects of use of antimalarials in systemic lupus erythematosus. J Rheumatol 25:983–985PubMed

29.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMed

30.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed

31.

Guzmán J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcón-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19:1551–1558PubMed

32.

Van Gestel AM, Haagsma CJ, Van Riel PLCM (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845–1850CrossRefPubMed

33.

Miller SA, Dykes DD, Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215–1219

34.

Manzi S, Meilahn EN, Rairie JE (1997) Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 145:408–415PubMed

35.

Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for CAD in patients with systemic lupus erythematosus. Am J Med 93:513–519PubMed

36.

Gladman DD, Urowitz MB (1987) Morbidity in systemic lupus erythematosus. J Rheumatol 14 [Suppl 13]:223–226

37.

De Duve C, De Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F (1974) Commentary. Lysosomotropic agents. Biochem Pharmacol 23:2495–2531CrossRefPubMed

38.

Nossen JO, Rustan AC, Barnard T, Drevon CA (1984) Inhibition by chloroquine of the secretion of very low density lipoproteins by cultured rat hepatocytes. Biochem Biophys Acta 803:11–20

39.

Rustan AC, Nossen JO, Tefre T, Drevon CA (1987) Inhibition of very low density lipoprotein secretion by chloroquine, verapamil, and monensin takes place in the Golgi complex. Biochem Biophys Acta 930:311–319

40.

Chen HW, Leonard DA (1984) Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells. J Biol Chem 259:8156–8162PubMed

41.

Beynen AC, Van Der Molen AJ, Geelen MJH (1981) Inhibition of hepatic cholesterol by biosynthesis by chloroquine. Lipids 16:472–474PubMed

42.

Goldstein JL, Brunschede GY, Brown MS (1975) Inhibition of the proteolytic degradation of low density lipoprotein in human fibroblasts by chloroquine, concanavalin A and Triton WR 1339. J Biol Chem 250:7854–7862PubMed

43.

Goldstein JL, Brown MS (1976) The LDL pathway in human fibroblast: a receptor mediated mechanism for the regulation of cholesterol metabolism. Curr Top Cell Regul 11:147–181PubMed

44.

Svenson KLG, Lithell H, Hallgren R, Vessby B (1987) Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides: I. Effects of anti-inflammatory and disease modifying drug treatment. Arch Intern Med 147:1917–1920PubMed

Titel: Polymorphism of the β3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine
verfasst von: J.F. Muñoz-Valle
M. Vázquez-Del Mercado
S. Ruiz-Quezada
E. Oregón-Romero
R.E. Navarro-Hernández
J. Ramírez-Barragán
G. Martínez-Bonilla
G. Bernard-Medina
B.E. Bastidas-Ramírez
B. Ruiz-Madrigal
A. Panduro
Publikationsdatum: 01.05.2003
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 3/2003
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-002-0266-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Polymorphism of the β₃-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2003

Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome

Ex vivo apoptosis, CD95 and CD28 expression in T cells of children with juvenile idiopathic arthritis

Peripheral T cell lymphoma-associated hemophagocytic syndrome in a patient with human adjuvant disease

A challenging case of rheumatoid arthritis in an acromegalic patient

Functional disability and quality of life in patients with ankylosing spondylitis

Juvenile chronic arthritis in a monozygotic twin couple

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin